ReviewBiomedical reports2026
Progress in targeted therapy for prostate cancer via cell surface proteins (Review).
Review in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa), particularly metastatic castration-resistant PCa, remains a significant therapeutic challenge. Cell-surface proteins have emerged as promising therapeutic targets. The present review examines the biological characteristics of PCa cell surface proteins focusing on major targets, such as prostate-specific membrane antigen, six-transmembrane epithelial antigen 1, trophoblast cell-surface antigen 2, and prostate stem cell antigen. These targets provide the foundation for the development of emerging therapeutic strategies, including radioligand therapy, antibody-drug conjugates, and bispecific T cells and chimeric antigen receptor T cell therapy. Combining the latest clinical trial data, the present review discusses the efficacy of targeted therapy, the mechanisms of drug therapy resistance, and combination treatment strategies, analyzing their potential application in the management of PCa and exploring prospects for the development of precision therapy in the future. Additionally, this review aims to systematically summarize the relevant progress in this field. In conclusion, the findings provide a theoretical basis and clinical guidance for molecular-targeted therapy in PCa, thereby promoting further research and applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.